Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Epkinly (epcoritamab-bysp) is a bispecific antibody that simultaneously binds CD3 on T-cells and CD20 on B-cells, redirecting the patient's own T-cells to destroy CD20-expressing lymphoma cells. It is jointly developed by AbbVie and Genmab.
Epkinly is FDA-approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after 2 or more lines of systemic therapy, and for relapsed or refractory follicular lymphoma after 2 or more prior therapies. In November 2025, the FDA additionally approved Epkinly combined with rituximab and lenalidomide for relapsed or refractory follicular lymphoma.
By bridging T-cells and CD20-positive lymphoma cells, epcoritamab activates the T-cells to directly kill the cancer cells, independent of the tumor's own antigen-presentation machinery.
Epkinly is given by subcutaneous injection using a step-up dosing schedule during the first treatment cycle to reduce the risk of cytokine release syndrome, followed by scheduled maintenance doses, as determined by the treating hematologist-oncologist.
Boxed Warning — Epkinly: Epkinly can cause cytokine release syndrome (CRS), including serious or fatal reactions, and immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening and fatal reactions. Patients are monitored closely following each dose during the step-up dosing period, and premedication is used to reduce risk. Epkinly also increases the risk of serious infections and cytopenias.
Monitor closely after each dose, particularly during step-up dosing. Manage with supportive care, tocilizumab, and/or corticosteroids as needed, per treatment protocol.
Monitor for confusion, tremor, difficulty speaking, or seizures. Interrupt or discontinue treatment as needed.
Serious infections, including fatal infections, have occurred. Monitor for signs of infection throughout treatment.
Neutropenia, thrombocytopenia, and anemia can occur. Monitor blood counts regularly.
Epkinly can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Epkinly (epcoritamab-bysp) is jointly developed and commercialized by AbbVie and Genmab, and received its most recent FDA approval expansion in November 2025 for follicular lymphoma combined with rituximab and lenalidomide.
Import of Epkinly through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of lymphoma diagnosis and prior treatment history, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Epkinly directly from AbbVie's authorized supply chain to ensure product authenticity and regulatory compliance.
Epkinly is sourced through verified, GDP-compliant, cold-chain channels from AbbVie's authorized supply chain to ensure authenticity and quality.
Epkinly should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Epkinly is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Epkinly through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support lymphoma diagnosis and treatment coordination for Epkinly access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Epkinly.
Bangalore's oncology network offers access to lymphoma treatment planning for eligible patients.
Chennai-based specialists coordinate Epkinly access alongside comprehensive lymphoma care.
Hyderabad's cancer care institutions support patients pursuing Epkinly therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Epkinly.
Pune-based hematologists assist with diagnosis confirmation and Epkinly treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Epkinly.
Kochi's oncology units assist patients with the documentation needed for Epkinly access.
Chandigarh's cancer care centers support Epkinly treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Epkinly access process.
Lucknow-based cancer centers assist patients pursuing Epkinly therapy.
Bhubaneswar's oncology institutions support access to Epkinly for eligible patients.
Guwahati's specialists help coordinate Epkinly access for patients across the Northeast.
Patients in other cities across India can also access Epkinly through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
